8 Einträge gefunden

1. Long Term Efficacy and Safety of Secukinumab in the Treatment of the Multiple Manifestations of Psoriatic Disease

   1. Reich, K
   2. Warren, R B
   3. Coates, L C
   4. Di Comite, Gabriele

   2020 - Forschungsinformationssystem des UKE
2. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

   1. Blauvelt, A
   2. Papp, K
   3. Gottlieb, A
   4. Jarell, A
   5. Reich, K
   6. Maari, C
   7. Gordon, K B

   2020 - Forschungsinformationssystem des UKE
3. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

   1. Kimball, A B
   2. Kerbusch, T
   3. van Aarle, F
   4. Kulkarni, P
   5. Li, Q
   6. Blauvelt, A
   7. Papp, K A

   2020 - Forschungsinformationssystem des UKE
4. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

   1. Kimball, A B
   2. Papp, K A
   3. Reich, K
   4. Gooderham, M
   5. Li, Q
   6. Cichanowitz, N
   7. La Rosa, C

   2020 - Forschungsinformationssystem des UKE
5. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

   1. Reich, K
   2. Augustin, M
   3. Thaçi, D
   4. Pinter, A
   5. Leutz, A
   6. Henneges, C
   7. Schneider, E

   2020 - Forschungsinformationssystem des UKE
6. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

   1. Reich, K
   2. Warren, R B
   3. Iversen, L
   4. Puig, L
   5. Pau-Charles, I
   6. Igarashi, A
   7. Ohtsuki, M

   2020 - Forschungsinformationssystem des UKE
7. A new treatment option for paediatric psoriasis

   1. Reich, K

   2020 - Forschungsinformationssystem des UKE
8. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

   1. Reich, K
   2. Puig, L
   3. Szepietowski, J C
   4. Paul, C
   5. Lacour, J P
   6. Tsianakas, A
   7. Sieder, C

   2020 - Forschungsinformationssystem des UKE